Antiproliferative effects of novel aliphatic acetogenin analogs against aggressive solid tumor cell lines

In Vivo

Volumn 25, Issue 2, 2011, Pages 203-207

  León, Leticia G ^a,b   Giovannetti, Elisa ^b,c   Alecci, Claudia ^b   Giancola, Fiorella ^b   Funel, Niccola ^c   Zucali, Paolo ^d   Peters, Godefridus J ^b   Padrón, José M ^a  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Universities Hospitals of Pisa   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Aliphatic acetogenins; Anticancer drugs; Cell cycle; Mesothelioma; Pancreas cancer

Indexed keywords

ACETOGENIN; FLUOROURACIL; GEMCITABINE; PEMETREXED; PROTEIN KINASE B;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DISRUPTION; CELL GROWTH; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PANCREAS ADENOCARCINOMA; PANCREATIC DUCTAL ADENOCARCINOMA; PANCREATIC DUCTAL ADNOCARCINOMA; PLEURA MESOTHELIOMA; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE; TUMOR CELL LINE;

EID: 79955033776     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bailly C: Ready for a comeback of natural products in oncology. Biochem Pharmacol 77: 1447-1457, 2009.
2. Butler MS: Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep 25: 475-516, 2008.
3. Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397-1421, 2006.
4. Brandt K, Christensen LP, Hansen-Møller J, Hansen SL, Haraldsdottir J, Jespersen L, Purup S, Kharazmi A, Barkholt V, Frøkiær H and Kobæk-Larsen M: Health-promoting compounds in vegetables and fruits: A systematic approach for identifying plant components with impact on human health. Trends Food Sci Technol 15: 384-393, 2004. (Pubitemid 38583554)
5. Ding H, Chin Y-W, Kinghorn AD and D'Ambrosio SM: Chemopreventive characteristics of avocado fruit. Seminars Cancer Biol 17: 386-394, 2007. (Pubitemid 47369170)
6. Padrón JM, Miranda PO, Padrón JI and Martín VS: β′-Hydroxy-α,β-unsaturated ketones: A new pharmacophore for the design of anticancer drugs. Bioorg Med Chem Lett 16: 2266-2269, 2006.
7. León LG, Carballo RM, Vega-Hernández MC, Miranda PO, Martín VS, Padrón JI and Padrón JM: β′-Hydroxy- α,β-unsaturated ketones: A new pharmacophore for the design of anticancer drugs. Part 2. Chem Med Chem 3: 1740-1747, 2008.
8. Govindan R, Kratzke RA, Herndon JE 2nd, Niehans GA, Vollmer R, Watson D, Green MR and Kindler HL: Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11: 2300-2304, 2005. (Pubitemid 40490190)
9. Krug LM: An overview of chemotherapy for mesothelioma. Hematol Oncol Clin North Am 19: 1117-1136, 2005.
10. Dowell JE and Kindler HL: Antiangiogenic therapies for mesothelioma. Hematol Oncol Clin North Am 19: 1137-1145, 2005.
11. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C and Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003. (Pubitemid 46606305)
12. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004. (Pubitemid 38410779)
13. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M and Danesi R: Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther 5: 1387-1395, 2006. (Pubitemid 44070474)
14. Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J and Winograd B: Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 27: 897-900, 1991.
15. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J and Boyd M: Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757-766, 1991.
16. Butt AJ, Roberts CG, Seawright AA, Oelrichs PB, MacLeod JK, Liaw TYE, Kavallaris M, Somers-Edgar TJ, Lehrbach GM, Watts CK and Sutherland RL: A novel plant toxin, persin, with in vivo activity in the mammary gland, induces Bim-dependent apoptosis in human breast cancer cells. Mol Cancer Ther 5: 2300-2309, 2006. (Pubitemid 44530467)
17. Feng FY, Varambally S, Tomlins SA, Chun PY, Lopez CA, Li X, Davis MA, Chinnaiyan AM, Lawrence TS and Nyati MK: Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene 26: 3431-3439, 2007. (Pubitemid 46788888)
18. Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E, Leon LG, Pollina LE, Groen A, Falcone A, Danesi R, Campani D, Verheul HM and Boggi U: MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 70: 4528-4538, 2010.
19. 1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci 96: 2110-2115, 1999. (Pubitemid 29117876)
20. Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, Gartel A and Hay N: Activation of Akt/protein kinase B overcomes a G(2)/M cell cycle checkpoint induced by DNA damage. Mol Cell Biol 22: 7831-7841, 2002. (Pubitemid 35217294)